Format

Send to

Choose Destination
J Am Dent Assoc. 2017 Jan;148(1):17-25. doi: 10.1016/j.adaj.2016.08.025.

Efficacy and safety of Chinese patent medicines in the treatment of recurrent aphthous stomatitis: A systematic review.

Abstract

BACKGROUND:

Recurrent aphthous stomatitis (RAS) is the most common chronic oral mucosal condition of the oral cavity. Investigators in clinical trials have evaluated the effectiveness of Chinese patent medicines in the treatment of RAS. However, the results are conflicting rather than conclusive. To evaluate the efficacy and safety of Chinese patent medicines for the treatment of RAS, the authors conducted a systematic review.

TYPES OF STUDIES REVIEWED:

The authors searched 9 electronic databases to identify randomized controlled trials (RCTs) or potential clinical controlled trials (CCTs), published in any language, in which the investigators compared Chinese patent medicines with vitamin tablets or placebos for the treatment of RAS.

RESULTS:

The authors included 11 RCTs and 1 CCT in the review. Results showed that Chinese patent medicines were beneficial for patients with RAS in relieving ulcer pain and reducing the duration and frequency of attacks. The reported adverse effects of Chinese patent medicines included stomachache, abdominal distention, diarrhea, mild nausea, and gastrointestinal discomfort, which were either self-limiting or could be relieved by treatment cessation.

CONCLUSIONS AND PRACTICAL IMPLICATIONS:

Chinese patent medicines may be effective for treatment of RAS by means of relieving pain and reducing ulcer size and episode duration and frequency.

KEYWORDS:

Chinese patent medicine; Recurrent aphthous stomatitis; efficacy; safety; systematic review

PMID:
28062049
DOI:
10.1016/j.adaj.2016.08.025
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center